Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (SAB BIO), whose exchange-listed warrants trade under the symbol SABSW, is a clinical-stage biopharmaceutical company that regularly issues news about its lead program SAB-142 and its broader human immunoglobulin platform. Company press releases describe SAB BIO as focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders, with a primary emphasis on autoimmune type 1 diabetes (T1D).
News coverage for SAB BIO often centers on clinical milestones for SAB-142, a multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for Stage 3 T1D. Recent announcements include positive Phase 1 safety and pharmacodynamic data, initiation and enrollment progress in the Phase 2b SAFEGUARD trial, and presentations of SAB-142 data at major diabetes conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management.
Investors following SABSW-related news will also see updates on SAB BIO’s corporate and financial developments. The company has reported participation in healthcare investor conferences, financing transactions such as the private placement of Series B Convertible Preferred Stock and warrants, and governance updates including board appointments. SEC-related announcements, such as proxy materials for stockholder meetings to approve share issuances and equity plan amendments, are another recurring theme.
Because SAB BIO’s strategy is to advance SAB-142 as a therapy that may change the treatment paradigm for autoimmune type 1 diabetes, many news items highlight mechanistic data, safety findings, and trial design details that support this goal. For readers tracking SABSW and SAB Biotherapeutics, the news stream provides insight into clinical progress, regulatory interactions, capital structure decisions, and scientific visibility through conference presentations. Bookmarking this page allows ongoing access to company press releases and third-party coverage linked to SABSW and the underlying SAB Biotherapeutics common stock.
SAB Biotherapeutics (Nasdaq: SABS) closed an underwritten public offering on March 19, 2026 of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 shares at a public offering price of $3.85 per share (pre-funded warrants at $3.8499).
Gross proceeds were approximately $85 million before fees. The company granted underwriters a 30-day option to buy up to 3,311,688 additional shares. Net proceeds will primarily fund continued development and trials of SAB-142, manufacturing, regulatory activities, and general corporate purposes.
SAB BIO (Nasdaq: SABS) priced an underwritten public offering to raise approximately $85 million in gross proceeds through the sale of 19,324,677 common shares and pre-funded warrants to purchase up to 2,753,246 shares.
The offering is expected to close on or about March 19, 2026, with a 30-day underwriter option to buy up to 3,311,688 additional shares; net proceeds will fund clinical development of SAB-142, manufacturing, regulatory and general corporate purposes.
SAB Biotherapeutics (Nasdaq: SABS) commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants on March 17, 2026. The company also plans to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities.
Proceeds, together with existing cash and marketable securities, are intended primarily to fund continued development of SAB-142 (clinical trials, manufacturing, regulatory), and for working capital and general corporate purposes. The offering is made on a Form S-3 shelf registration declared effective January 7, 2026, and is subject to market conditions.
SAB BIO (Nasdaq: SABS) reported additional Phase 1 data for SAB-142 in adults with established type 1 diabetes showing early signals of C‑peptide preservation at Day 120 in treated participants versus placebo. The small cohort (n=6; 4 treated, 2 placebo) showed biomarker evidence of T‑cell exhaustion. SAB‑142 has advanced to the registrational Phase 2b SAFEGUARD trial with topline data expected 2H 2027.
SAB BIO (Nasdaq: SABS) reported full‑year 2025 results and business highlights. Key developments include dosing multiple patients in the registrational Phase 2b SAFEGUARD study with enrollment on track to complete by end‑2026 and topline data expected in 2H 2027.
Other milestones: positive Phase 1 data supporting safety and redosability of SAB‑142, a $175 million oversubscribed private placement (with strategic investor Sanofi), and a cash position of $143.5 million providing runway through 2028.
SAB Biotherapeutics (Nasdaq: SABS) said members of management will participate in two investor conferences in Miami Beach in March 2026: the Leerink Partners Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11 at 8:30 a.m. ET.
Both appearances are in a fireside chat format. According to the company, live webcasts and archived recordings will be available in the Investors & Media section of the company website at www.sab.bio.
SAB Biotherapeutics (Nasdaq: SABS) announced that management will participate in two investor conferences in February 2026: Guggenheim Securities Emerging Outlook: Biotech Summit on February 11, 2026 (10:30 a.m. ET, New York) and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 (8:40 a.m. ET, virtual).
According to the company, both appearances include fireside chats and will be available live and on demand via the Investors & Media section of the company website at www.sab.bio.
SAB BIO (Nasdaq: SABS) announced two board appointments effective January 7, 2026: David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director.
Management highlights Zaccardelli's 20+ years of biopharma leadership and his role in the successful launch of Ohtuvayre, and describes Jain's two decades of experience in autoimmune and inflammatory disease drug development. Both appointees are presented as bringing complementary expertise to support clinical execution and advancement of SAB-142, the company's fully human anti-thymocyte immunoglobulin candidate for type 1 diabetes and other autoimmune diseases.
SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.
A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.
SAB BIO (Nasdaq: SABS) announced the first patient was dosed with SAB-142 in the Phase 2b registrational SAFEGUARD trial on Dec 18, 2025. The trial targets stage 3 type 1 diabetes using a fully human anti-thymocyte immunoglobulin intended as a disease-modifying therapy. Enrollment is ongoing at multiple global sites, including the U.S., Australia, and New Zealand, with European sites joining soon. The company plans to share Phase 2b data in 2H 2027.